Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs
- 1 December 1996
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 22 (3) , 351-364
- https://doi.org/10.1016/s0169-409x(96)00449-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954European Journal Of Cancer, 1995
- Thymidine kinase-mediated killing of rat brain tumorsJournal of Neurosurgery, 1993
- Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir. National Institutes of HealthHuman Gene Therapy, 1993
- Herpes Simplex-1 Virus Thymidine Kinase Gene Is Unable to Completely Eliminate Live, Nonimmunogenic Tumor Cell VaccinesJournal of Immunotherapy, 1992
- In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain TumorsScience, 1992
- Phenotypic conversion of TK-deficient cells following electroporation of functional TK enzymeExperimental Cell Research, 1992
- Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteinsNature, 1985
- Activated cyclophosphamide: An enzyme-mechanism-based suicide inactivator of DNA polymerase/3??5? exonucleaseZeitschrift für Krebsforschung und Klinische Onkologie, 1984
- The chemotherapeutic exploitation of virus-specified enzymesAdvances in Enzyme Regulation, 1980
- Tumour-growth inhibitorynitrofphenylaziridines and related compounds structure-activity relationshipsChemico-Biological Interactions, 1969